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Abstract: Natural killer (NK) cells are key players in the innate immune response. They kill 
virus-infected cells and are crucial for the induction of adaptive immune responses. Marek's 
disease virus (MDV) is a highly contagious alphaherpesvirus that causes deadly T cell lymphomas 
in chickens. Host resistance to MDV is associated with differences in NK cell responses; however, 
the exact role of NK cells in the control of MDV remains unknown. In this study, we assessed if 
MDV can infect NK cells and alter their activation. Surprisingly, we could demonstrate that 
primary chicken NK cells are very efficiently infected with very virulent RB-1B MDV and the 
live-attenuated CVI988 vaccine. Flow cytometry analysis revealed that both RB-1B and CVI988 
enhance NK cell degranulation and increase interferon gamma (IFNγ) production in vitro. In 
addition, we could show that the MDV Eco Q-encoded oncogene (meq) contributes to the induction 
of NK cell activation using meq knockout viruses. Taken together, our data revealed for the first 
time that NK cells are efficiently infectable with MDV and that this oncogenic alphaherpesvirus 
enhances NK cell degranulation and increased IFNγ production in vitro. 
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1. Introduction 
Marek’s disease virus (MDV) is an alphaherpesvirus that causes deadly lymphomas in chickens 
with a mortality of up to 100% [1]. The development of the lymphoproliferative disease is 
accompanied by clinical signs including immunosuppression, torticollis, ataxia, and paralysis [1]. In 
infected animals, MDV productively infects chicken B and T cells [2–4] and establishes latency 
mostly in CD4+ T cells [5]. In addition, it has been recently shown that MDV can also infect certain 
phagocytes and endothelial cells [6–8]. Upon infection of chickens, MDV activates both innate and 
adaptive immune responses [9]. One of the cell types involved in the early MDV-specific immune 
response are natural killer (NK) cells [10].  
NK cells are major components of the innate immune system and belong to group I innate 
lymphocytes. These cells are known to rapidly kill virus-infected cells [11,12] and play a crucial role 
in tumor immunosurveillance [13]. Activation of NK cells leads to degranulation of cytotoxic 
granules containing perforin and granzyme and production of various cytokines including 
interferon gamma (IFNγ) [14]. IFNγ is involved in activation of the adaptive immune system [15,16] 
and orchestrates the expression of interferon inducible genes [17]. Interestingly, NK cell responses 
are thought to be involved in resistance to MDV [18], as NK cell activity is elevated in MDV-resistant 
chickens when compared to susceptible lines [10,19]. Moreover, vaccination against MDV has been 
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shown to enhance NK cell activity, which is associated with a better vaccine protection [20]. 
Unfortunately, until now very little was known about the interplay of MDV with NK cells and their 
response to infection. In a previous study, we identified markers that are expressed on chicken NK 
cells and developed assays to measure NK cell degranulation and killing [21]. Here we used these 
tools and recombinant viruses to determine if MDV can infect NK cells and if this affects NK cell 
degranulation and IFNγ secretion. 
We demonstrate that both a very virulent strain and the CVI988 vaccine strain efficiently infect 
primary chicken NK cells. In these infected cultures, we observed an increased NK cell 
degranulation and IFNγ production. Moreover, we demonstrate that the increased NK cell 
degranulation is dependent on the expression of the major MDV oncogene meq [22]. Our study 
provides the first evidence that NK cells are efficiently infected, highlighting a so far unknown 
tropism of this highly oncogenic herpesvirus. 
2. Materials and Methods  
2.1. Cells  
Chicken embryo cells (CEC) were isolated from 11-day-old VALO specific-pathogen-free (SPF) 
embryos (VALO Biomedia; Osterholz-Scharmbeck, Germany) as described previously [23]. CECs 
were maintained in minimal essential medium (MEM, PAN Biotech; Aidenbach, Germany) 
supplemented with 1%–10% fetal bovine serum (PAN Biotech) and 100 U/ml penicillin and 100 
μg/ml streptomycin (AppliChem; Darmstadt, Germany) at 37 °C and 5% CO2.  
Splenocytes were isolated from 14-day-old Novogen brown embryos, which we obtained from 
a commercial hatchery (Verbeek; Zeewolde, The Netherlands). At this developmental stage, a 
population of cells that resemble mammalian NK cells is abundantly present in the embryonic 
spleen. These cells lack surface expression of T or B cell-specific antigens and are able to kill a 
NK-susceptible target cell line [24]. We will refer to this population as NK cells. NK cells were 
maintained in Iscove Modified Dulbecco Medium (IMDM) supplemented with 2% heat inactivated 
fetal bovine serum, 8% heat inactivated chicken serum (Biochrom; Berlin, Germany), 100 U/ml 
penicillin, 100 μg/ml streptomycin and 2 mM glutamax I (Gibco; Carlsbad, CA, USA), which we 
refer to as “NK medium”. NK cells were isolated as previously described [21]. Briefly, spleens were 
homogenized using a 70 μM cell strainer (Beckton Dickinson (BD); Franklin Lakes, NJ, USA) to 
obtain a single cell suspension. Viable cells were then purified by Ficoll–Paque density gradient 
centrifugation [25], resuspended in NK medium and used directly or stored in liquid nitrogen until 
further use. 
2.2. Viruses 
MDV reporter viruses expressing the green fluorescent protein (GFP) under the control of the 
herpes simplex virus 1 (HSV-1) thymidine kinase promotor were generated based on the very 
virulent RB-1B field strain and the vaccine strain CVI988. GFP was inserted into the bacterial 
artificial chromosome (BAC) backbone replacing the Escherichia coli gpt gene (Eco-gpt). The 
RB-1BΔmeq virus was generated by en-passant mutagenesis (Figure S1) as described previously 
[26,27] using the primers provided in Table S1. All recombinant GFP reporter viruses were 
reconstituted by transfection of fresh CEC with purified BAC DNA using CaPO4 transfection [28]. 
The viruses were propagated on CEC for up to six passages, and infected cells were stored in liquid 
nitrogen. 
2.3. Growth Kinetics and Plaque Assays  
The replication properties of all recombinant viruses were determined by plaque size assays 
and quantitative PCR (qPCR)-based multi-step growth kinetics. For plaque size assays, one million 
CEC were infected with 100 plaque-forming units (PFU) of each virus and MDV plaques were 
analyzed at 6 days post infection (dpi). Images of at least 50 randomly selected plaques were taken 
and plaque areas determined using Image J (National Institutes of Health, USA). For multi-step 
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growth kinetics, 6 well plates were infected with 100 PFU of each virus in each well. Every day, one 
well was harvested, and DNA extracted using the Invisorb® DNA Tissue HTS 96 Kit (Stratec 
Molecular; Berlin, Germany) according to the manufacturer’s instructions. MDV genome copies 
were determined by qPCR as we described previously [4] using the primers and probes provided in 
Table S1. Growth kinetics and plaque sizes were determined in three independent experiments. 
2.4. Infection of NK cells 
GFP-expressing RB-1B or CVI988-infected CEC and uninfected CEC (mock) were thawed and 
seeded into a 24 well cell culture plate with PFUs ranging from 2.5 × 104 to 105. In parallel, primary 
NK cells were labeled with a PKH26 red fluorescent cell linker kit (Sigma-Aldrich; Zwijndrecht, The 
Netherlands) according to the manufacturer’s protocol. 2×105 cells/ml labeled NK cells were added 
to the uninfected and infected CEC monolayer. Cultures were incubated at 37 °C and 5% CO2 for 4 
hours (CD107 surface expression analysis), or 6 hours (analysis of IFNγ production). Additionally, 
co-cultures of GFP-labeled viruses and unlabeled NK cells were performed, which were incubated 
for up to 72 hours to assess infectivity of these viruses in NK cells.  
2.5. CD107 Assay 
The CD107 assay was used as previously described with some minor modifications [21]. Briefly, 
Golgistop (BD) was added to the cells in a final dilution of 1:1000, together with an allophycocyanin 
(APC)-conjugated mouse anti-chicken CD107 monoclonal antibody (mouse anti-chicken LEP-100, I 
(IgG1), clone 5G10. Developmental Studies Hybridoma Bank (DSHB); University of Iowa, IA, USA). 
To separate wells containing NK cells in the absence of virus, phorbol-12-myristate 13-acetate 
(PMA)/ionomycin (Sigma-Aldrich) and medium were added as positive and negative control 
respectively, as previously described [21]. After co-culturing virus-infected CEC and NK cells for 4 
hours at 37 °C/5% CO2, non-adherent cells were harvested for flow cytometry. 
2.6. IFNγ Assay 
To analyze interferon gamma (IFNγ) production by NK cells, Golgiplug (BD) was added to 
each well of the co-cultures in a final dilution of 1:1000 followed by an incubation of 6 hours at 37 
°C/5% CO2 before non-adherent cells were harvested for flow cytometry. 
2.7. Flow Cytometry 
In experiments with unlabeled NK cells, the non-adherent cells were stained with an APC 
conjugated mouse-anti-chicken CD45 antibody (LT40, IgM, Southern Biotech; Birmingham, AL, 
USA) for 20 minutes at 4 °C. Next, cells were washed and resuspended in a fluorescence activated 
cell sorting (FACS) buffer made of PBS supplemented with 0.5% bovine serum albumin (BSA) and 
0.005% NaN3. For CD107 measurements, the non-adherent cells were washed and resuspended in 
FACS buffer. 
To analyze IFNγ by intracellular cytokine staining, the non-adherent cells were washed in FACS 
buffer and permeabilized for 10 minutes with 0.5 ml of 1 volume of FACS permeabilizing solution 
(BD), 1 volume of FACS lysing solution (BD), and 8 volumes of water. Next, cells were washed in 
FACS buffer and stained with an APC-conjugated mouse-IgG1 anti-chicken IFNγ antibody 
(mAb80), kindly provided by Dr. Lowenthal [29]. After a 20 minute incubation at 4 °C, the cells were 
washed and resuspended in FACS buffer. 
At least 50,000 cells in the lymphocyte gate were acquired using a FACS Canto flow cytometer 
(BD). Data were analyzed with FlowJo (Tree Star Inc.; Ashland, OR, USA). NK cells were selected as 
either CD45 positive or PKH26 positive cells. Cells that were double positive for CD45 and GFP or 
PKH26 and GFP were defined as MDV-infected chicken NK cells. 
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2.8. Statistical Analyses 
Non-parametric statistical tests were used when the assumption of normal distributed data 
were not met. A p-value of <0.05 was considered statistically significant. All statistical analyses were 
performed using the program GraphPad Prism 7.05 (GraphPad Software, Inc.; La Jolla, CA, USA). 
3. Results and Discussion 
3.1. Reporter Viruses Replicate to Comparable Levels 
To assess the ability of MDV to infect NK cells, we used GFP expressing reporter viruses. To 
confirm that the reporter viruses replicate in a comparable manner, we performed plaque size assays 
and multi-step growth kinetics as described above. Plaque size assays revealed that all reporter 
viruses efficiently replicate at comparable levels. (Figure 1A, Figure S2). We confirmed these results 
using qPCR-based multi-step growth kinetics (Figure 1B). These results are in line with the 
replication of previously generated reporter viruses [30,31]. 
3.2. MDV Can Readily Infect Chicken NK Cells 
Next, we assessed the ability of RB-1B and the CVI988 vaccine to infect primary NK cells by 
co-cultivation with infected CEC. To our surprise, we could very efficiently infect chicken NK cells at 
levels between 20 and 75 percent depending on the dose of infection after 4 and 24 hours post 
infection (Figure 1C,D). The rate of infection was thereby dependent on the PFU present in the 
inoculum. Higher infection rates were observed for RB-1B (Figure 1C) when compared to CVI988 
(Figure 1D), indicating that a virulent virus infects NK cells more efficiently.  
 
Figure 1. Virus in vitro characterization and natural killer (NK) cell infection rates. (A) Plaque size 
assays and (B) multi-step growth kinetics of indicated viruses (p > 0.05, one-way analysis of variance 
(ANOVA)). (C) NK-cell infection rates upon infection with the very virulent RB-1B strain and (D) the 
Marek's disease virus (MDV) vaccine strain CVI988 at 4 and 24 hours post infection with different 
plaque forming units (PFU): black = 105 PFU, dark gray = 5 × 104 PFU, light gray = 2.5 × 104 PFU. Error 
bars represent the standard error of the mean. 
These infection rates were higher than observed in primary B and T cells [32], in primary 
endothelial cells [8], and in primary macrophages [7]. In those cells, infection rates ranged from 2%–
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20%. Notably, we optimized the B cell infection system since it was published [32] and readily 
achieve infection rates of about 50% in primary chicken B cells in vitro. 
3.3. MDV Enhances NK Cell Degranulation and Increases IFNγ Production 
To investigate the effect of MDV on NK cell activation, we performed co-cultures of MDV and 
primary NK cells and analyzed NK cell activation by measuring CD107 surface expression as a 
proxy for degranulation and the production of interferon gamma (IFNγ) by flow cytometry. Prior to 
co-cultivation, NK cells were labeled with the fluorescent dye PKH26 to allow efficient 
discrimination between NK cells and infected CEC. PKH26 positive cells were selected within the 
single cell population. It is important to note that CD3 is not expressed in these cells as described 
previously [21]. Based on forward and side scatter, we selected the lymphocyte population and 
assessed the CD107 surface expression. Next, we analyzed the GFP expression within the CD107 
positive cells by gating on the GFP positive or GFP negative cells (Figure 2). 
 
Figure 2. Gating strategy to determine CD107 positive and interferon gamma (IFNγ) positive NK 
cells. (A) We gated single cells based on forward scatter-area (FSC-A) and forward scatter-width 
(FSC-W). (B) Within the single cells, PKH26 labeled NK cells were gated for the subsequent analysis 
of CD107 expression (D–G) and IFNγ expression (H–K). (C) We found that CD107 was expressed on 
cells with a low forward scatter. (D) IFNγ plotted against FSC-A scatter showed one population of 
cells that expressed IFNγ. (E) Lymphocytes were gated based on forward and side scatter. (F) Within 
this gate, we selected the CD107 positive cells and determined GFP positive cells in (G) 
MDV-infected and (H) mock-infected cultures. (I) Lymphocytes were gated based on FSC-A and side 
scatter-area (SSC-A). (J) We then selected the IFNγ producing cells within the lymphocyte gate and 
subsequently determined GFP positive cells in (K) MDV-infected and (L) mock-infected cultures. 
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When NK cells were incubated with 100,000 PFU of the virulent strain RB-1B, CD107 expression 
increased from 1.56% to 3.51% compared to the mock (p > 0.05). A similar trend was observed in a 
co-culture of NK cells with CVI988 (Figure 3A). Furthermore, we investigated if MDV infections 
induce IFNγ production by intracellular cytokine staining, since the expression of CD107 is known 
to correlate with IFNγ production [21]. Again, single cells were gated and within that population, 
we selected the PKH26 positive NK cells. We could readily detect a population of IFNγ positive cells 
(Figure 2D) and determine the amount of IFNγ positive lymphocytes (Figure 2J) as well as the GFP 
expression within the IFNγ positive cells (Figure 2K). Here, the production of IFNγ significantly 
increased upon co-cultures with RB-1B and CVI988 compared to mock (Figure 3B). Taken together, 
we could demonstrate that RB-1B and CVI988-infected NK cells show higher levels of surface CD107 
and an increased IFNγ production when compared to mock-infected cells (Figure 3A,B). Overall, 
this suggests that NK cells are activated in these cultures. Interestingly, we observed that only the 
small population of CD107+ cells was infected with MDV, suggesting that the infection could be a 
consequence of NK cell activation. The same is true for T cell infections by the virus, as it is known 
that activation is a crucial step for MDV infection of primary chicken T cells [33]. 
3.4. Lower Rates of Activation in the Absence of the Major MDV Oncogene meq  
Finally, to provide a possible mechanistic explanation for the enhanced NK cell activation, we 
investigated the role of the major MDV oncogene meq on CD107 expression and IFNγ production. 
meq has a plethora of functions including up and downregulation of cellular and viral genes and 
impacts a variety of disease-associated pathways; however, its full functional significance is not yet 
completely understood, despite being the most studied MDV gene [34,35].  
 
Figure 3. NK cell activation rates and IFNγ production. (A) Assessment of CD107+ cells and (B) IFNγ 
production upon infection of NK cells with RB-1B vs CVI988. The same assays were performed to 
determine differences in (C) the percentage of CD107+ cells and (D) IFNγ production comparing 
infections of NK cells with RB-1B and the RB-1BΔmeq mutant. Asterisks indicate statistically 
significant differences to mock-infected cells (* p > 0.05, Kruskal–Wallis test). Error bars represent the 
standard error of the mean. 
To assess the role of meq in the NK cell activation, we used a recombinant virus with a deletion 
of the meq gene. We could demonstrate that the CD107 surface expression on chicken NK cells is 
comparable to the mock-infected cells upon infection with the meq deletion mutant, while RB-1B and 
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CVI988 that express meq induced CD107 (Figure 3C). Interestingly, the levels of IFNγ production 
were not affected in the absence of meq (Figure 3D).  
Although both degranulation and IFNγ production can be induced upon NK cell activation, 
these functions are not necessarily executed by one NK cell subset. Different NK cell subsets have 
been described in humans and mice, based on marker expression and function [15,36]. In chickens 
however, characterization of NK cells subsets is still in its infancy [37]. Differential effects of MDV 
wild type and mutant viruses on various NK cell subsets could be a likely explanation for the 
observed effect of the meq deletion mutant.  
Our data suggests that meq influences NK cell activation and thereby adds another piece to the 
puzzle of the wide range of functions of this virulence factor. 
4. Conclusions 
Taken together, we demonstrated that chicken NK cells can be efficiently infected with MDV 
and thereby shed light on an extended host cell tropism for the virus. Furthermore, our in vitro data 
demonstrate enhanced NK cell degranulation and release of IFNγ, which could be part of their 
antiviral response to MDV infections. Future studies will address the role of NK cells in MDV 
infection in vivo using NK cell knockout chickens that are hopefully available in the years to come 
[38].  
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Generation 
of recombinant viruses, Figure S2: Representative plaque images, Table S1: Primers and TaqMan probes used in 
this study. 
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